Evolution of the Average Target: Compass Therapeutics, Inc.

Evolution of the Target Price: Compass Therapeutics, Inc.

Changes in Analyst Recommendations: Compass Therapeutics, Inc.

e5e2f38f32415ee.rumbRLqHGIbpdhUSeHDuLBcNm1ncd9cu8B-7o_fuxaU.xIKtK87Yd7OmLkdYAQWselxKrG-dNed_lGb44oSJgsDe0KgB99Z3saVFWA~e3c0b709bf39c5f9d28a2def0047cd95
04-28 Raymond James Downgrades Compass Therapeutics to Market Perform From Outperform MT
04-27 Wedbush Lowers Compass Therapeutics Price Target to $5 From $8, Maintains Outperform Rating MT
01-05 William Blair Initiates Compass Therapeutics at Outperform MT
12-03 Canaccord Genuity Initiates Compass Therapeutics at Buy With $10 Price Target MT
12-03 Cantor Fitzgerald Initiates Compass Therapeutics at Overweight MT
02/04/25 Leerink Partners Upgrades Compass Therapeutics to Outperform From Market Perform, Adjusts PT to $6 From $4 MT
24/02/25 Guggenheim Initiates Compass Therapeutics at Buy With $12 Price Target MT
19/02/25 Piper Sandler Initiates Compass Therapeutics at Overweight MT
16/09/24 Ladenburg Thalmann Upgrades Compass Therapeutics to Buy From Neutral MT
31/01/23 Jefferies Starts Compass Therapeutics at Buy With $8 Price Target MT
27/01/23 Stifel Initiates Compass Therapeutics at Buy With $9 Price Target MT
16/12/22 EF Hutton Initiates Compass Therapeutics at Buy With $10.30 Price Target MT
10/11/22 Raymond James Adjusts Price Target on Compass Therapeutics to $8 From $5, Maintains Outperform Rating MT
03/11/22 HC Wainwright Adjusts Compass Therapeutics' Price Target to $10 From $12, Keeps Buy Rating MT
23/05/22 HC Wainwright Assumes Compass Therapeutics at Buy, Price Target Set at $12 MT
05/05/22 SVB Leerink Adjusts Compass Therapeutics' Price Target to $11 from $9, Keeps Outperform Rating MT
15/03/22 Ladenburg Thalmann Initiates Compass Therapeutics at Buy With $7 Price Target MT
19/01/22 B. Riley Starts Compass Therapeutics at Buy with $10 PT, Says Well-Positioned to Benefit from Potential Biotech Sector Turnaround MT
22/12/21 Raymond James Starts Compass Therapeutics at Outperform With $5 Price Target MT
20/12/21 SVB Leerink Starts Compass Therapeutics at Outperform With $12 Price Target MT
15/12/21 Wedbush Starts Compass Therapeutics at Outperform With $8 Price Target MT
19/11/21 Roth Capital Initiates Compass Therapeutics at Buy Rating With $15 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+20.78%
+16.43%
+55.42%
+18.16%
+21.45%
+14.99%
+3.89%
+28.57%
-7.96%
Average +19.08%
Weighted average by Cap. +20.55%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.180USD
Average target price
8.917USD
Spread / Average Target
+309.02%
High Price Target
24.00USD
Spread / Highest target
+1,000.92%
Low Price Target
5.000USD
Spread / Lowest Target
+129.36%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. CMPX Stock
  4. CMPX Stock
  5. Consensus Compass Therapeutics, Inc.
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!